Losartan, U.S FDA approved Ag-II antagonist improves the reach of oHSV into the tumor mass via disturbing transforming growth factor beta 1 (TGF-β1) signaling and subsequently declining production of stromal collagen in the tumor microenvironment of human breast, pancreatic and skin desmoplastic tumor models in mice (Diop-Frimpong et al., 2011). The gene discussed is TGFB1; the disease is neoplasm.